Pulmocide presents clinical update from promising antifungal program at 2019 Respiratory Innovation Summit
London, UK; 17 May 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, announced today that it has been invited to present at the 2019 Respiratory Innovation Summit (RIS) being held today in Dallas, Texas.
Dr Peter Strong, Pulmocide’s Chief Scientific Officer, will present in the RIS Innovations Showcase at the event. His presentation will include an update on Pulmocide’s clinical development programmes and highlight recent clinical data with PC945 for the treatment of invasive fungal infections in patients who have undergone lung transplantation.
Dr Garth Rapeport, Chief Executive Officer of Pulmocide, said: “We were delighted by the invitation to present at the RIS, the leading showcase for respiratory innovation. Pulmocide has made significant progress in the discovery of a novel inhaled treatment for pulmonary Aspergillus infections and we are looking forward to presenting emerging clinical data for PC945.”
- Ends -
For further information, please contact:
Pulmocide Ltd
Garth Rapeport, Chief Executive Officer
+44 203 763 9484
admin@pulmocide.com
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Lindsey Neville
+44 20 3709 5700
pulmocide@consilium-comms.com
About PC945
PC945 is the first triazole antifungal agent to be developed for delivery to the lung via inhalation. Inhaled delivery has the advantage of low dose administration, targeted delivery to the site of action and minimal systemic liability. Results from a Phase 1 study showed PC945 to be safe and well tolerated and pharmacokinetic data confirmed prolonged lung retention with once daily use.
As a potent antifungal agent, PC945 is currently being developed for the treatment of Aspergillus infections in patients with asthma, cystic fibrosis and following lung transplantation. Phase 2 studies have recently commenced to assess the effectiveness of PC945 for the treatment of invasive Aspergillus infections in an expanded access population.
About Pulmocide
Pulmocide Ltd http://pulmocide.com/ is a venture capital funded company based in London with a focus on novel inhaled therapies for life threatening lung infections caused by Aspergillus (a fungal pathogen) and Respiratory Syncytial Virus (RSV).
Lung infections caused by Aspergillus result from an infection in the bronchial mucosa and are considered ideal for the use of inhaled medicines. The Pulmocide team has a long track record in the discovery and development of inhaled medicines. Pulmocide has identified PC945 (a potent antifungal agent) and PC786 (antiviral compound) for delivery by inhaled administration. Dosing has been initiated in Phase 2 studies with both product candidates.